Adaptive Biotechnologies (ADPT) Equity Ratio (2018 - 2026)

Adaptive Biotechnologies has disclosed Equity Ratio across 9 years of filings, most recently posting 0.43 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.43, up 14.83% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.43 (up 14.83% YoY), and the FY2025 annual result was 0.43, up 13.67% from the prior year.
• Equity Ratio came in at 0.43 for Q1 2026 at Adaptive Biotechnologies, roughly flat from 0.43 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.64 in Q1 2022 to a low of 0.36 in Q2 2025.
• The 5-year median for Equity Ratio is 0.44 (2024), against an average of 0.47.
• Across the five-year window, Equity Ratio declined 20.56% in 2024 and gained 14.83% in 2026, its largest moves.
• Adaptive Biotechnologies' Equity Ratio stood at 0.54 in 2022, then dropped by 13.93% to 0.47 in 2023, then slipped by 19.49% to 0.38 in 2024, then rose by 13.67% to 0.43 in 2025, then rose by 0.21% to 0.43 in 2026.
• The last three Equity Ratio figures came in at 0.43 (Q1 2026), 0.43 (Q4 2025), and 0.42 (Q3 2025), per Business Quant data.